**ABSTRACT**

**BACKGROUND/OBJECTIVES:** Many studies have suggested that *Rhus verniciflua* Stokes (RVS) and its extract are anticancer agents. However, RVS had limited use because it contains urushiol, an allergenic toxin. By improving an existing allergen-removal extraction method, we developed a new allergen-free *Rhus verniciflua* Stokes extract (RVSE) with higher flavonoid content. In this study, we examined whether RVSE inhibits the ability of AGS gastric cancer cells to migrate and invade.

**MATERIALS/METHODS:** The flavonoids content of RVSE was analyzed by HPLC. The effects of RVSE on migration and invasion in AGS cells were analyzed by each assay kit. Matrix metalloproteinase (MMP)-9, plasminogen activator inhibitor-1 (PAI-1) and urokinase-type plasminogen activator (uPA) protein expression was analyzed by protein antibody array. The phosphorylation of signal transducer and activator of transcription (STAT) 3 were assayed by Western blot analysis.

**RESULTS:** RVSE treatment with 0–100 μg/mL dose-dependently reduced the ability of AGS cells to migrate and invade. Notably, treatment with RVSE strongly inhibited the expression of MMP-9 and uPA and the phosphorylation of STAT3. In contrast, RVSE treatment dramatically increased the expression of PAI-1. These results indicate that the inhibition of MMP-9 and uPA expression and STAT3 phosphorylation and the stimulation of PAI-1 expression contributed to the decreased migration and invasion of AGS cells treated with RVSE.

**CONCLUSIONS:** These results suggest that RVSE may be used as a natural herbal agent to reduce gastric cancer metastasis.

**Keywords:** Gastric cancer; metastasis; matrix metalloproteinases; urokinase-type plasminogen activator; plasminogen activator inhibitors

**INTRODUCTION**

Despite a decrease in incidence in the recent decade, gastric cancer is still one of the most common causes of cancer death worldwide [1]. In South Korea, gastric cancer is the most frequent cancer and the fourth most common cause of cancer death. In countries with a high
Conflict of Interest
The authors declare no potential conflicts of interests.

Author Contributions
Conceptualization: Park SJ, Kim EJ; Formal analysis: Lee HS, Jung JI, Kim KH; Funding acquisition: Park SJ, Kim EJ; Investigation: Lee HS, Jung JI, Kim EJ; Methodology: Jung JI, Kim KH, Kim EJ; Supervision: Kim EJ; Writing - original draft: Lee HS, Jung JI; Writing - review & editing: Kim EJ.

Incidence of gastric cancer, such as Korea and Japan, a nationwide early screening system was introduced to improve the early detection rate of gastric cancer, thereby increasing its 5-year survival rate compared to other cancers [2]. However, because stomach pain is seen only in advanced stages of gastric cancer, the cure rate decreases sharply if not detected early. The probability of metastasis increases as gastric cancer progresses; more than 80% of advanced gastric cancer patients have metastasis to lymph nodes [3]. Patients with early gastric cancer can increase their survival rate compared to other cancers with conventional treatment methods such as surgery, chemotherapy and radiation therapy. However, these conventional therapies are not entirely appropriate for advanced gastric cancer patients as well. The cause of death of an advanced gastric carrier patient is metastasis, so it is the measures to address the metastasis that is needed [4].

Metastasis is associated with more than 90% of cancer-associated mortality [5]. Cancer cells of the primary tumor invade the surrounding tissues locally to intravasation of the lymphatic and vascular system, where they survive and migrate to the microvessels of the distant tissues through the bloodstream (extravasation). There, they adapt to the unfamiliar environment of these tissues, survive and produce secondary tumors through cell proliferation (colonization) [6]. Thus, it is a valid approach to prevent metastasis in order to effectively treat cancers, including gastric cancer. Bioactive compounds obtained naturally have been noticed as new agents for metastasis prevention.

*Rhus verniciflua* Stokes (RVS) belongs to the Anacardiaceae family, usually known as the lacquer tree. RVS has been used as a traditional herbal medicine for the relief of pain caused by various diseases, such as cancer, as well as the treatment of digestive system diseases in East Asian countries, such as Korea, Japan, and China [7,8]. RVS contains numerous useful compounds, such as quercetin, fustin, fisetin, sulfuretin, and butein. Previous research has shown that *Rhus verniciflua* Stokes extract (RVSE) has antioxidant, anti-proliferative, anti-inflammatory, and anti-tumor effects [8-18]. Several *in vivo* and *in vitro* studies demonstrated antitumor effects of RVSE and/or its compounds in gastric, breast, liver, lymphoma, and osteosarcoma [13,19,20]. The mechanism of the antitumor effect of RVS is still uncertain, but possible mechanisms include inhibition of the phosphoinositol-3-kinase (PI3K)-Akt/protein kinase B pathway [20], activation of AMP-activated protein kinase (AMPK) [21], cell cycle arrest [22], decreased manganese superoxidase activity or glutathione content [23], activation of caspase, downregulation of Bcl-2 and Mcl-1, upregulation of Bax, P53 hyperphosphorylation, and S6 hypophosphorylation [7].

Despite the pharmacological effects of RVS, its use has been limited because it contains an allergenic substance, urushiol (a mixture of several derivatives of catechol). Therefore, removing urushiol from RVSE is critical for its safe use. Allergen-free RVSE, as well as common RVSE, have been reported to have growth inhibitory and apoptosis-inducing effects in A549 human lung cancer cells [7] and have been shown to be useful in the treatment of advanced or metastatic cancers [19]. However, the components contained in allergen-free RVSE and their subsequent effects have been shown to differ depending on the specific method of detoxification (removing urushiol). Thus, it is possible to maximize the specific effect by modifying the detoxification method [17]. We modified the existing extract method to create a new, concentrated and purified allergen-free RVSE. Analysis of the compound showed that this RVSE contained 69.8% and 48.6% more fustin and fisetin, respectively, compared to those extracted by the conventional method. This study was conducted to investigate the effect of this new RVSE on metastasis in AGS cells, a human gastric cancer cell line.
MATERIALS AND METHODS

Materials
The materials used in this research were purchased from the following suppliers: RPMI1640 and fetal bovine serum (FBS) from Welgene (Daegu, Korea); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), anti-β-actin antibody from Sigma-Aldrich (St. Louis, MO, USA); antibodies against signal transducer and activator of transcription (STAT) 3 (PY705) and STAT3 from Cell Signaling Technology (Beverly, MA, USA); antibodies against matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); antibodies against urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) from Calbiochem (Darmstadt, Germany); Unless noted otherwise, all other materials were purchased from Sigma-Aldrich.

Preparation of RVSE
RVSEs were prepared by Medience Co., Ltd. (Chuncheon, Korea). Dried RVS cultivated in Chuncheon, Korea were purchased from an herbal medicine store (Chuncheon, Korea). Dried RVS were sliced to 2 cm, after which, 100 g of sliced RVS was refluxed in 1 L of water at 100°C for 10 h. This extraction procedure was repeated twice. The extracts were filtered through Whatman filter paper #2, after which the filtrate was freeze-dried. The resulting powder was used as pre-\textit{Rhus verniciflua} Stokes extract (pRVSE). To prepare concentrated and refined RVSEs, 100 g of pRVSE was refluxed in 1 L of 95% ethanol at room temperature for 1 h. The extract was centrifuged at 3,000 rpm for 10 min, after which the supernatant was collected and dried below 60°C in a vacuum. The resulting powder was used as RVSE. The pRVSE and RVSE extracts were stored −20°C until further use.

High-performance liquid chromatography (HPLC) analysis
Both pRVSE and RVSE were analyzed using HPLC (SPD-20A; Shimadzu, Tokyo, Japan) with a C18 column packed with 5 µm diameter particles (250 × 4.6 mm, YMC-Pack ODS-A, YMC Co., Ltd., Kyoto, Japan) and detection at 520 nm. Fustin and fisetin used as reference standards were purchased from Biopurity Phytochemicals Ltd. (Chengdu, China). The operating conditions were as follows. The mobile phase solvents used were 5% acetic acid, methanol, and acetonitrile (70:20:10). The flow rate and injection volume were 1.0 mL/min and 10 µL, respectively. Before performing HPLC, the samples and reference standards were dissolved in methanol and filtered through 0.45 µm filters. The chromatographic peaks of the analytes were confirmed by comparing their ultraviolet spectra and retention time with those of the reference standards.

Cell culture and cell viability assay
AGS human gastric adenocarcinoma cells were acquired from the American Type Culture Collection (Manassas, VA, USA). AGS cells were cultured in RPMI1640 containing 100 mL/L FBS, 100,000 U/L penicillin and 100 mg/L streptomycin at 37°C in a humidified atmosphere of 5% CO₂ in air. To determine cell viability, the cells were plated in 24-well plates at 5 × 10⁴ cells/well and incubated for 24 h. After 24 h, the cells were treated with pRVSE or RVSE at concentrations ranging from 0 to 150 µg/mL and incubated for 24 h. pRVSE and RVSE were dissolved in dimethyl sulfoxide (DMSO). DMSO was applied to all cells until they reached a final concentration of 0.01%. Cell viability was determined by MTT assay as described previously [24].

In vitro migration assay
The ability of AGS cells to migrate was determined using the CytoSelect™ 24-well cell Migration Assay kit (Cell Biolabs Inc., San Diego, CA, USA). The AGS cells were serum-deprived in
RPMI1640 supplemented with 10 mL/L FBS (serum-deprivation medium) for 24 h. The serum-deprived AGS cells were plated in 8 µm pore size polycarbonate membrane inserts in 24-well plates at 1.5 × 10⁵ cells/insert and treated with the different concentrations of pRVSE and RVSE in serum-deprivation medium. The lower chamber of the well was filled with RPMI1640 containing 100 mL/L hormone-free, gelatinase-free FBS as a chemoattractant. After 4 h of incubation, the migrated cells were stained with hematoxylin and eosin and observed with a light microscope. To quantify the migration ability, the migrated cells were stained with the CytoSelect™ Cell Stain Solution and Extraction Solution to extract the dye stain. Then, the absorbance was measured at 560 nm with a microplate reader, according to the manufacturer’s instructions.

**In vitro invasion assay**
The invasion ability of AGS cells was measured using 8 µm pore size polycarbonate membrane inserts coated with dried basement membrane matrix solution contained in the CytoSelect™ 24-well Cell Invasion Assay kit (Cell Biolabs Inc.). The invasion assay was performed in the same way as the migration assay detailed above.

**Preparation of conditioned media and cell lysates**
AGS cells were plated in 100 mm dishes at 1 × 10⁶ cells/dish and incubated for 24 h. Next, the cells were serum-deprived in serum-deprivation medium for 24 h and treated with the indicated concentration of RVSE for 24 h. Media conditioned for 24 h were collected. The cells were lysed as described previously [25]. The protein contents of the conditioned media and cell lysates were determined using a BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer’s instruction.

**Protein antibody array**
Conditioned media and cell lysates were analyzed by a Proteome Profiler™ Antibody Array kit (R&D Systems, Minneapolis, MN, USA) to estimate the expression levels of various angiogenesis (metastasis)-related proteins, according to the manufacturer’s instructions. The relative abundance of each protein spot was quantified using an Image Quant™ LAS 500 imaging system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The expression levels were normalized to the control protein.

**Western blot analysis**
Western blot analyses were performed as described previously [25]. Blots were detected with Luminata™ Forte Western HRP Substrate (Millipore Corporation, Billerica, MA, USA). The relative intensity of each protein band was quantified using an Image Quant™ LAS 500 imaging system (GE Healthcare Bio-Sciences AB). The expression levels were normalized to β-actin expression.

**Statistical analyses**
All results were presented as the mean ± SEM. The statistical significance of results among the treatment group differences was analyzed via one-way analysis of variance, followed by Duncan’s multiple range test. Differences were considered significant at *P* < 0.05.

**RESULTS**

**Quantification of flavonoid contents of RVSE**
As a result of analyzing the flavonoid components of pRVSE and RVSE with HPLC, urushiol was not detected in both pRVSE and RVSE, and fustin and fisetin were detected in pRVSE.
and RVSE. RVSE has an increased fustin and fisetin content than pRVSE. pRVSE contained 129 mg/g and 57 mg/g of fustin and fisetin, respectively, while RVSE contained 219 mg/g and 82 mg/g of fustin and fisetin, respectively. These HPLC results indicate that RVSE, a product of the concentration and refining process, contained more flavonoids including fustin and fisetin (Fig. 1).

**Effect of RVSE on cell viability of AGS cells**

Prior to investigating the effect of pRVSE and RVSE on the migration of AGS cells, an MTT assay was done in order to determine the pRVSE and RVSE concentrations shown to be non-cytotoxic to AGS cells. pRVSE significantly increased AGS cell viability at 50 and 100 µg/mL concentrations but did not affect viability at 150 µg/mL. RVSE did not affect cell viability at concentrations ranging from 25 to 100 µg/mL. However, the viability of cells treated with 150 µg/mL of RVSE was significantly decreased compared to the non-treated cells (Fig. 2). Based on these results, the subsequent experiments were conducted at concentrations of 0-100 µg/mL to exclude the possibility that the inhibition of migration and invasion of AGS cells was due to cytotoxic effects of pRVSE and RVSE.
Effect of RVSE on the migration and invasion of AGS cells

To compare the effect of pRVSE and RVSE on the migratory ability of AGS cells, we conducted an in vitro migration assay. As shown in Fig. 3, pRVSE and RVSE dose-dependently inhibited the migration of AGS cells. However, when cells were treated with the same concentration of pRVSE and RVSE, the number of migrated cells was markedly reduced by RVSE treatment compared to pRVSE treatment. These results indicate that RVSE may inhibit AGS cells migration more than pRVSE.

We subsequently attempted to determine whether RVSE inhibits the invasive ability of AGS cells. RVSE inhibited the invasion of AGS cells in a dose-dependent manner. Treating AGS cells with 100 µg/mL of RVSE resulted in a 52.7 ± 3.2% reduction in the number of cells invaded (Fig. 4).

Effect of RVSE on metastasis-related proteins expression in AGS cells

To determine the mechanisms by which RVSE inhibits the migration and invasion of AGS cells, we measured the relative expression levels of metastasis (angiogenesis)-related proteins in total cell lysates and conditioned media using a Proteome Profiler™ Antibody Array kit. Among the 55 kinds of proteins measureable with the kit, MMP-9 protein expression was markedly decreased and PAI-1 protein expression was dramatically increased in the total cell lysates and conditioned media of cells treated with 100 µg/mL RVSE (data not shown). To validate these results, we subsequently performed Western blot analyses of total cell lysates for MMP-9 and PAI-1. As shown in Fig. 5, RVSE significantly inhibited MMP-9 protein expression in AGS cells. PAI-1 protein expression was markedly increased by RVSE treatment. Treatment of AGS cells with 100 µg/mL RVSE resulted in a 443 ± 60% increase in PAI-1 protein expression. In addition to PAI-1, the effect of RVSE on uPA protein expression was investigated. RVSE dose-dependently inhibited the uPA protein expression in AGS cells (Fig. 6).

Effect of RVSE on the phosphorylation of STAT3 in AGS cells

We next determined the effect of RVSE on the phosphorylation of STAT3 by Western blot analysis. RVSE significantly suppressed the phosphorylation of STAT3 in AGS cells dose-dependently. The protein expression of STAT3 in AGS cells was not altered by RVSE treatment (Fig. 7).
Anti-metastatic effect of Rhus verniciflua Stokes

Fig. 3. Effect of pRVSE and RVSE on the migration of AGS cells.
The migration ability of AGS cells was measured using the CytoSelect™ 24-well Cell Migration Assay kit. The cells were serum-deprived in DMEM supplemented with 10 mL/L charcoal-stripped FBS for 24 h. Serum-deprived cells were plated in trans-well inserts in 24-well plates at 1.5 × 10^5 cells/filter and treated with 0–100 µg/mL pRVSE or RVSE. The lower chamber of the well was filled with SDM supplemented with 1g/L BSA as a chemoattractant. The cells were then incubated for 4 h. (A) The migrated cells were stained with hematoxylin and eosin. (B) The migrated cells were stained with cell stain solution and quantified by measuring the absorbance at 560 nm after dye extraction. Each bar represents the mean ± SEM (n = 4). Means without a common letter differ, P < 0.05.

pRVSE, pre-Rhus verniciflua Stokes extract; RVSE, Rhus verniciflua Stokes extract; DMEM, Dulbecco's Modified Eagle's Medium; FBS, fetal bovine serum; SDM, serum-deprivation medium; BSA, bovine serum albumin.

Fig. 4. Effect of RVSE on the invasion of AGS cells.
The invasion ability of AGS cells was measured using the CytoSelect™ 24-well Cell Invasion Assay kit. Serum-deprived AGS cells were plated in trans-well inserts in 24-well plates at 1.5 × 10^5 cells/filter and treated with 0–100 µg/mL RVSE. The lower chamber of the well was filled with SDM supplemented with 1g/L BSA as a chemoattractant. The cells were then incubated for 6 h. The invaded cells were stained with cell stain solution and quantified by measuring the absorbance at 560 nm after dye extraction. Each bar represents the mean ± SEM (n = 4). Means without a common letter differ, P < 0.05.

RVSE, Rhus verniciflua Stokes extract; SDM, serum-deprivation medium; BSA, bovine serum albumin.
Fig. 5. Effect of RVSE on MMP-9 protein expression in AGS cells. Cells were plated in 100 mm dishes at \(1 \times 10^5\) cells/dish in DMEM containing 100 mL/L FBS. After 24 h, the cells were serum-deprived with SDM for 24 h. After serum-deprivation, the cells were incubated with 0–100 µg/mL RVSE for 24 h. The cell lysates were subjected to Western blotting with MMP-9 antibody. (A) Photographs of chemiluminescent detection of the blots, which are representative of 3 independent experiments, are shown. (B) Quantitative analysis of the blots. The relative abundance of each band to its own \(\beta\)-actin was quantified, and the control levels were set at 1. Each bar represents the adjusted mean ± SEM \((n = 4)\). Means without a common letter differ, \(P < 0.05\).

RVSE, *Rhus verniciflua* Stokes extract; MMP, matrix metalloproteinase; DMEM, Dulbecco's Modified Eagle's Medium; FBS, fetal bovine serum; SDM, serum-deprivation medium.

Fig. 6. Effect of RVSE on uPA and PAI-1 protein levels in AGS cells. The cells were plated and treated as described in Figure 5. The cell lysates were subjected to Western blotting with uPA and PAI-1 antibodies. (A) Photographs of chemiluminescent detection of the blots, which are representative of 3 independent experiments, are shown. (B) Quantitative analysis of the blots. The relative abundance of each band to its own \(\beta\)-actin was quantified, and the control levels were set at 1. Each bar represents the adjusted mean ± SEM \((n = 4)\). Means without a common letter differ, \(P < 0.05\).

RVSE, *Rhus verniciflua* Stokes extract; uPA, urokinase-type plasminogen activator; PAI-1 plasminogen activator inhibitor-1.

Fig. 7. Effect of RVSE on the phosphorylation of STAT3 in AGS cells. The cells were plated and treated as described in Fig. 5. The cell lysates were subjected to Western blotting with pY705 STAT3 and STAT3 antibodies. (A) Photographs of chemiluminescent detection of the blots, which are representative of 3 independent experiments, are shown. (B) Quantitative analysis of the blots. The relative fold-change in pSTAT3 to its own STAT3 was quantified, and the control levels were set at 1. Each bar represents the adjusted mean ± SEM \((n = 4)\). Means without a common letter differ, \(P < 0.05\).

RVSE, *Rhus verniciflua* Stokes extract; STAT, signal transducer and activator of transcription.
DISCUSSION

In the traditional East Asian medical system, traditional medicines have been used to treat various diseases, including cancer. As the scientific basis for their efficacy continues to be revealed, the potential use of traditional medicines as therapeutic agents has gained popularity, thanks to their low price, superb efficacy, and few side effects. RVS is also a traditional medicinal used in the Orient for centuries to treat digestive system diseases, liver detoxification, hemostasis, and cough. Previous studies have shown that RVS inhibited cell proliferation and induced apoptosis in tumor cells. In human gastric cancer cell line studies, RVS induced G1 phase cell cycle arrest and promoted the mitochondrial death pathway by inhibiting the PI3K-Akt/PIK3 pathway [20,22]. In an ovarian cancer cell line study, allergen-free RVSE promoted apoptosis through JNK activation [26]. In addition, the anticancer effects of RVS were reported in an in vitro study of various cancer cell lines, including Lewis lung carcinoma, non-small cell lung cancer, human lymphoma, osteosarcoma, and breast cancer cells [20,27-30]. Several case studies and clinical studies have reported positive effects of RVS, including tumor size reduction and prolonged survival time, in advanced and metastatic cancer patients [16,31-35].

In the past, despite these functional activities, the use of RVS has been very limited because it contains an allergen, named urushiol. So far, various methods of detoxification of RVS have been developed to remove urushiol, such as methods of utilizing organic solvents and oxidizers, enzymatic methods, and mushroom bacteria fermentation methods [36-38]. By the way, the main component and bioactivity of the RVS are very different according to the detoxification processing method [17]. Therefore, it is important to identify healthier and safer extraction methods that can selectively remove urushiol alone while preserving beneficial ingredients such as flavonoid compounds and phenolic compounds. Among them, considering the cost and safety aspects of the human body, the physical method using the loss of urushiol activity at high temperatures is known to be the most appropriate. pRVSE is also the removal of urushiol by high temperature extraction. We made RVSE by adding concentration and refining methods here. RVSE, like pRVSE, did not detect urushiol, and the content of fisetin and fustin increased (Fig. 1).

RVS contains various phytochemical components. About 40 types of compounds have been isolated. Of these compounds, three are phenolic acids, four are flavonols, four are flavanols, three are flavones, one is chalconoid, and 2 are tannins [39,40]. According to a study that analyzed the content of total phenolic and flavonoids compound by liquid chromatography with tandem mass spectrometry analysis on the skin, stem, and leaves of RVS, gallic acid, dihydroxybenzoic acid, methyl gallate, pentagalloyl glucose, fustin, quercitrin, taxifolin, garbanzol, kaempferol-3-O-rhamnoside, fisetin, sulfuretin, butein, and urushiol were detected. Among them, the content of three substances, methyl gallate, fustin, and quercitrin, was the highest [41].

Among the substances contained in RVS, butein [42-44], kaempferol and quercetin [40] have been studied for a lot of anticancer effects and mechanisms. Fisetin and fustin are expected to have similar efficacy as polyphenol compounds like these substances, but research on the anti-cancer effect of fisetin and fustin is still lacking. Fustin is a kind of flavonol that acts as an antioxidant, such as having a protective effect on 6-hydroxydopamine-induced neuronal cell death [45]. According to a recent comparative analysis of antioxidant activity of substances in Rhus typhina L. stem, fustin’s antioxidant activity was reported to be less than methyl
gallate, gallic acid and quercetin and greater than vitamin C and rutin [46]. Fisetin is a type of polyphenol belonging to the flavonoid group, and it contains a lot of fruits and vegetables such as strawberries and apples as well as RVS, and has excellent antioxidant properties [47].

Fisetin from RVS significantly reduced inflammatory cytokines such as tumor necrosis factor-α, interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 [48]. According to the in vitro studies, the anticancer activity of fisetin appears to be related to the down-regulation of AMPK, cyclooxygenase, epidermal growth factor receptor, extracellular signal regulated kinase, MMP, nuclear factor-kappa B, prostate-specific antigen, transcription factor T-cell factor, TNF-related apoptosis inducing ligand, Wnt inhibitory factor, X linked inhibitor of apoptosis, and PI3K/AKT/mTOR pathway [49-53]. Fisetin also showed anti-cancer effects in cells and animal models by influencing cell cycles [54] and acting as a topoisomerase inhibitor [55].

In this study, we investigated the effect of RVSE on cancer cell metastasis in gastric cancer cells, the most frequent cancer in Koreans. pRVSE and RVSE were not cytotoxic in AGS gastric cancer cells up to a concentration of 100 μg/mL (Fig. 2). Therefore, we observed migration by treating AGS cells with 0, 25, 50, and 100 μg/mL pRVSE and RVSE. The results showed that the number of migrated cells decreased with increasing concentrations of both pRVSE and RVSE. In particular, RVSE was found to reduce migration much more dose-dependently than pRVSE (Fig. 3A and B). In subsequent invasive studies, RVSE reduced the number of invaded cells in a dose-dependent manner (Fig. 4). Migration and invasion are crucial steps in metastasis. Our results indicate that RVSE may inhibit metastasis.

MMPs are a class of endopeptidases that degrade and remodel the extracellular matrix. The migration and invasion of cancer cells to surrounding tissues are mediated by MMPs, particularly MMP-2 and MMP-9 [56]. Studies to determine the molecular mechanism of anti-metastasis in AGS cells, showed that treatment with RVSE dose-dependently decreased the level of MMP-9 protein. This result confirmed that the RVSE-induced anti-metastasis pathway was associated with MMP-9 inhibition in AGS cells. The uPA expression was decreased and the PAI-1 expression was increased by RVSE treatment. uPA, also known as urokinase, is a serine protease. The primary physiological substrate of this enzyme is plasminogen, an inactive form of the serine protease plasmin. When plasmin is activated by uPA, it degrades the extracellular matrix and thus, uPA is considered as a cancer metastasis-promoting factor [57]. In contrast, PAI-1, also known as endothelial plasminogen activator inhibitor or serpin E1, is an inhibitor of tissue plasminogen activator (tPA) and uPA [58]. Our results showed that RVSE inhibited degradation of the extracellular matrix by inhibiting the activation of plasminogen, thereby inhibiting cancer metastasis.

STAT3 belongs to the STAT protein family. STAT3 regulates the expression of various genes in response to cell stimulation and plays an essential role in many cellular processes, such as cell growth and apoptosis [59]. In response to cytokines and growth factors, STAT3 is phosphorylated by receptor-associated Janus kinases and translocates to the cell nucleus where they act as transcription activators. For example, STAT3 induces the phosphorylation of amino acids at specific positions in response to ligands, such as interferons, epidermal growth factor, IL-5, IL-6, and mitogen-activated protein kinases [60-63]. Constitutive STAT3 activation has been correlated with various human cancers and usually suggests substandard prognosis [64-67]. Increased STAT3 activation in cancer cells has been shown to induce metastasis by causing changes in protein complexes that regulate the expression of
inflammatory genes [68]. In our study, RVSE treatment showed a dose-dependent reduction of phosphorylated STAT3 expression. Based on these results, RVSE with high fisetin and fustin content suppresses phosphorylation of STAT-3, thereby inhibiting MMP-9 and uPA expression, and this prevents metastasis by inhibiting the decomposing and reconstruction of the extracellular membrane of target tissue where metastasis will occur. In the future, the cell- and its surrounding microenvironment-based mechanisms in relation to the metastasis inhibitory effect of RVSE need to be studied in more diverse ways.

In conclusion, this in vitro study demonstrated that RVSE effectively inhibited migration and invasion of AGS cells. MMP-9, uPA, PAI-1, and STAT3 were identified as key mediators modulating the metastasis of AGS cells. MMP-9 and uPA expression and STAT3 phosphorylation were significantly decreased and PAI-1 expression was significantly increased by RVSE treatment. Our results showed that RVSE inhibited the migration and invasion of AGS cells, which was mediated through the down-regulation of MMP-9 and uPA and the up-regulation of PAI-1. We suggest that RVSE could be a natural compound candidate for a preventive and/or therapeutic agent against gastric cancer metastasis.

REFERENCES

1. Forman D, Barley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006;20:633-49.
2. Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50:303-16.
3. Akagi T, Shiraishi N, Kitano S. Lymph node metastasis of gastric cancer. Cancers (Basel) 2011;3:2141-59.
4. Werner M, Becker KF, Keller G, Höfler H. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 2001;127:207-16.
5. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
6. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
7. Jang IS, Park JW, Jo EB, Choi CK, Lee YW, Yoo HS, Park J, Kim J, Jang BC, Choi JS. Growth inhibitory and apoptosis-inducing effects of allergen-free Rhus verniciflua Stokes extract on A549 human lung cancer cells. Oncol Rep 2016;36:3037-43.
8. Lee KW, Um ES, Jung BB, Choi ES, Kim EY, Lee S, Jang E, Lee JH, Kim Y. Rhus verniciflua Stokes extract induces inhibition of cell growth and apoptosis in human chronic myelogenous leukemia K562 cells. Oncol Rep 2018;39:11417.
9. Jang H, Lee JW, Lee C, Jin Q, Lee MK, Lee CK, Lee MK, Hwang BY. Flavonol glycosides from the aerial parts of Gynostemma pentaphyllum and their antioxidant activity. Arch Pharm Res 2016;39:1232-6.
10. Jang HS, Kook SH, Son YO, Kim JG, Jeon YM, Jang YS, Choi KC, Kim J, Han SK, Lee KY, Park BK, Cho NP, Lee JC. Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochim Biophys Acta 2005;1726:309-16.
11. Jung CH, Jun CY, Lee S, Park CH, Cho K, Ko SG. Rhus verniciflua Stokes extract: radical scavenging activities and protective effects on H2O2-induced cytotoxicity in macrophage RAW 264.7 cell lines. Biol Pharm Bull 2006;29:1603-7.
12. Jung CH, Kim JH, Hong MH, Seog HM, Oh SH, Lee PJ, Kim GI, Kim HM, Um JY, Ko SG. Phenolic-rich fraction from *Rhus verniciflua* Stokes (RVS) suppress inflammatory response via NF-κB and JNK pathway in lipopolysaccharide-induced RAW 264.7 macrophages. *J Ethnopharmacol* 2007;110:490-7.

13. Kitts DD, Lim KT. Antitumorigenic and cytotoxic properties of an ethanol extract derived from *Rhus verniciflua* Stokes (RVS). *J Toxicol Environ Health A* 2001;64:357-71.

14. Lee JC, Lim KT, Jang YS. Identification of *Rhus verniciflua* Stokes compounds that exhibit free radical scavenging and anti-apoptotic properties. *Biochim Biophys Acta* 2002;1570:181-91.

15. Lee JC, Lee KY, Kim J, Na CS, Jung NC, Chung GH, Jang YS. Extract from *Rhus verniciflua* Stokes is capable of inhibiting the growth of human lymphoma cells. *Food Chem Toxicol* 2004;42:1383-8.

16. Lee SH, Choi WC, Kim KS, Park JW, Lee SH, Yoon SW. Shrinkage of gastric cancer in an elderly patient who received *Rhus verniciflua* Stokes extract. *J Altern Complement Med* 2010;16:497-500.

17. Lee SO, Kim SJ, Kim JS, Ji H, Lee EO, Lee HI. Comparison of the main components and bioactivity of *Rhus verniciflua* Stokes extracts by different detoxification processing methods. *BMC Complement Altern Med* 2018;18:242.

18. Lee JO, Moon JW, Lee SK, Kim SM, Kim N, Ko SG, Kim HS, Park SH. *Rhus verniciflua* extract modulates survival of MCF-7 breast cancer cells through the modulation of AMPK-pathway. *Biol Pharm Bull* 2014;37:84276.

19. Kim JH, Go HY, Jin DH, Kim HP, Hong MH, Chung WY, Park JH, Jang JB, Jung H, Shin YC, Kim SH, Ko SG. Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of *Rhus verniciflua* Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. *Cancer Lett* 2008;265:197-205.

20. Son YO, Lee KY, Lee JC, Jang HS, Kim JG, Jeon YM, Jang YS. Selective antiproliferative and apoptotic effects of flavonoids purified from *Rhus verniciflua* Stokes on normal versus transformed hepatic cell lines. *Toxicol Lett* 2005;155:115-25.

21. Kang SH, Hwang IH, Son E, Cho CK, Choi JS, Park SJ, Lee YL, Jung KC, Park JH. Conjugated linoleic acid inhibits Caco-2 colon cancer cell growth. *Am J Physiol Gastrointest Liver Physiol* 2002;283:G357-67.

22. Kang SA, Cho HJ, Kim EJ, Holthuizen PE, Park HS, Ha YL, Jung KC, Park JH. Trans-10,cis-12-conjugated linoleic acid inhibits ovarian cancer cell death via JNK activation. *Am J Chin Med* 2016;44:1719-35.

23. Kang KA, Piao MJ, Madduma Hewage SR, Ryu VS, Oh MC, Kwon TK, Chae S, Hyun JW. Fisetin induces apoptosis and endoplasmic reticulum stress in human non-small cell lung cancer through inhibition of the MAPK signaling pathway. *Tumour Biol* 2016;37:9615-24.
29. Kook SH, Son YO, Chung SW, Lee SA, Kim KG, Jeon YM, Lee JC. Caspase-independent death of human osteosarcoma cells by flavonoids is driven by p53-mediated mitochondrial stress and nuclear translocation of AIF and endonuclease G. Apoptosis 2007;12:1289-98.

30. Lee JC, Kim J, Jang YS. Ethanol-eluted extract of *Rhus verniciflua* Stokes inhibits cell growth and induces apoptosis in human lymphoma cells. J Biochem Mol Biol 2003;36:337-43.

31. Chae J, Lee S, Lee S. Potential Efficacy of Allergen Removed *Rhus Verniciflua* Stokes Extract to Maintain Progression-Free Survival of Patients With Advanced Hepatobiliary Cancer. Explore (NY) 2018;14:300-4.

32. Kim KS, Jung HS, Choi WC, Eo WK, Cheon SH, Cheon SH. A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, *Rhus verniciflua* Stokes extract. Integr Cancer Ther 2010;9:100-4.

33. Lee SH, Choi WC, Yoon SW. Impact of standardized *Rhus verniciflua* Stokes extract as complementary therapy on metastatic colorectal cancer: a Korean single-center experience. Integr Cancer Ther 2009;8:148-52.

34. Lee SH, Kim KS, Choi WC, Yoon SW. Successful outcome of advanced pulmonary adenocarcinoma with malignant pleural effusion by the standardized *Rhus verniciflua* Stokes extract: a case study. Explore (NY) 2009;5:242-4.

35. Lee SK, Jung HS, Eo WK, Lee SY, Kim SH, Shim BS. *Rhus verniciflua* Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases. Ann Oncol 2010;21:1383-5.

36. Choi HS, Yeo SH, Jeong ST, Choi JH, Park HS, Kim MK. Preparation and characterization of urushiol free fermented *Rhus verniciflua* stem bark (FRVSB) extracts. Korean J Food Sci Technol 2012;44:173-8.

37. Kobayashi S, Ikeda R, Oyabu H, Tanaka H, Uyama H. Artificial urushi: design, synthesis, and enzymatic curing of new urushiol analogues. Chem Lett 2000;29:1214-5.

38. Choi HS, Kim MK, Park HS, Yun SE, Mun SP, Kim JS, Sapkota K, Kim S, Kim TY, Kim SJ. Biological detoxification of lacquer tree (*Rhus verniciflua* Stokes) stem bark by mushroom species. Food Sci Biotechnol 2007;16:935-42.

39. Kim JH, Jung CH, Jang BH, Go HY, Park JH, Choi YK, Hong SI, Shin YC, Ko SG. Selective cytotoxic effects on human cancer cell lines of phenolic-rich ethyl-acetate fraction from *Rhus verniciflua* Stokes. Am J Chin Med 2009;37:609-20.

40. Kim JH, Shin YC, Ko SG. Integrating traditional medicine into modern inflammatory diseases care: multitargeting by *Rhus verniciflua* Stokes. Mediators Inflamm 2014;2014:154561.

41. Jang JY, Shin H, Lim JW, Ahn JH, Jo YH, Lee KY, Hwang BY, Jung SJ, Kang SY, Lee MK. Comparison of antibacterial activity and phenolic constituents of bark, lignum, leaves and fruit of *Rhus verniciflua*. PLoS One 2018;13:e0200257.

42. Khan N, Adhami VM, Afaq F, Mukhtar H. Butein induces apoptosis and inhibits prostate tumor growth *in vitro* and *in vivo*. Antioxid Redox Signal 2012;16:1195-204.

43. Samoszuk M, Tan J, Chorn G. The chalcone butein from *Rhus verniciflua* Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts. BMC Complement Altern Med 2005;5:5.

44. Yit CC, Das NP. Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. Cancer Lett 1994;82:65-72.
47. Grynkiewicz G, Demchuk OM. New perspectives for fisetin. Front Chem 2019;7:697.
48. Lee JD, Huh JE, Jeon G, Yang HR, Woo HS, Choi DY, Park DS. Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int Immunopharmacol 2009;9:268-76.
49. Lall RK, Adhami VM, Mukhtar H. Dietary flavonoid fisetin for cancer prevention and treatment. Mol Nutr Food Res 2016;60:1396-405.
50. Hostetter GL, Ralston RA, Schwartz SJ. Flavones: food sources, bioavailability, metabolism, and bioactivity. Adv Nutr 2017;8:423-35.
51. Kashyap D, Sharma A, Sak K, Tuli HS, Bhattar HS, Bishayee A. Fisetin: a bioactive phytochemical with potential for cancer prevention and pharmacotherapy. Life Sci 2018;194:75-87.
52. Wang TY, Li Q, Bi KS. Bioactive flavonoids in medicinal plants: structure, activity and biological fate. Asian J Pharm Sci 2018;13:12-23.
53. Syed DN, Adhami VM, Khan MI, Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem 2013;13:995-1001.
54. Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S, Aggarwal BB. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys 2014;559:91-9.
55. Salerno S, Da Settimo F, Taliani S, Simorini F, La Motta C, Fornaciari G, Marini AM. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Curr Med Chem 2010;17:4270-90.
56. Freije JM, Balbín M, Pendás AM, Sánchez LM, Puente XS, López-Otín C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107.
57. Tang L, Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 2013;67:179-82.
58. Andersen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
59. Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB, Chin YE. Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol 2004;24:9390-400.
60. Akira S, Nishio Y, Inoue M, Wang X, Choi DM, Sudo T, Naruto M, Kishimoto T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994;77:63-71.
61. Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol Biosyst 2006;2:536-50.
62. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004;23:8017-23.
63. Tkach M, Rosembli C, Rivas MA, Proietti CJ, Díaz Flaqué MC, Mercogliano MF, Beguelin W, Maronna E, Guzmán P, Gercovich FG, Deza EG, Elizalde PV, Schillaci R, p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer 2013;20:197-212.
64. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006;66:3162-8.
65. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 2006;6:107-21. PUBMED | CROSSREF

66. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T, Sekine I. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 2006;15:1445-51. PUBMED | CROSSREF

67. Yin W, Cheepala S, Roberts IN, Syson-Chan K, DiGiovanni J, Clifford JL. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer 2006;5:15. PUBMED | CROSSREF

68. Vlahopoulos SA. Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode. Cancer Biol Med 2017;14:254-70. PUBMED | CROSSREF